Trial Profile
Phase II, Multi-Centre, Open-Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare
- 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 15 Dec 2016 Results assessing efficacy and safety of sorafenib in treatment-naive patients with metastatic renal cell carcinoma published in the BJU International.
- 03 Jul 2013 New source identified and integrated (German Clinical Trials Register; DRKS00004057).